Early stage prostate cancer treated with radiation therapy: Stratifying an intermediate risk group

International Journal of Radiation Oncology Biology Physics

Volumn 38, Issue 3, 1997, Pages 569-573

  Lattanzi, Joseph P ^a   Hanlon, Alexandra L ^a   Hanks, Gerald E ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

Hormonal therapy; Pretreatment PSA; Prostate carcinoma; PSA nadir

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT SELECTION; PRIORITY JOURNAL; PROSTATE CARCINOMA; RADIATION DOSE; RISK ASSESSMENT; SURVIVAL TIME;

AGED; AGED, 80 AND OVER; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PATIENT SELECTION; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE;

EID: 0030825491     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(97)00100-4     Document Type: Article

References (21)

1. Corn, B. W.; Hanks, G. E.; Schultheiss, T. E.; Hunt, M. A.; Lee, W. R.; Coia, L. R. Conformal treatment of prostate cancer with improved targeting: Superior prostate-specific antigen response compared to standard treatment. Int. J. Radiat. Oncol. Biol. Phys. 32:325-330; 1995.
2. Frazier, H. A.; Robertson, J. E.; Humphrey, P. A.; Paulson, D. F. Is prostate specific antigen of clinical importance in evaluating outcome after radical prostatectomy. J. Urol. 149:516-518; 1993.
3. Hanks, G. E.; Lee, W. R.; Schultheiss, T. E. Clinical and biochemical evidence of control of prostate cancer at 5 years after external beam radiation. J. Urol. 154:456-459; 1995.
4. Hudson, M. A.; Bahnson, R. R.; Catalona, W. J. Clinical use of prostate specific antigen in patients with prostate cancer. J. Urol. 142:1011-1017; 1989.
5. Kavadi, V. S.; Zagars, G. K.; Pollack, A. Serum prostate-specific antigen after radiation therapy for clinically localized prostate cancer: Prognostic implications. Int. J. Radiat. Oncol. Biol. Phys. 30:279-287; 1994.
6. Landmann, C.; Hunig, R. Prostatic-specific antigen as an indicator of response to radiotherapy in prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 17:1073-1076; 1989.
7. Lee, W. R.; Hanks, G. E.; Schultheiss, T. E.; Corn, B. W.; Hunt, M. A. Localized prostate cancer treated by external-beam radiotherapy alone: Serum prostate-specific antigen-driven outcome analysis. J. Clin. Oncol. 13:464-469; 1995.
8. Lee, W. R.; Hanlon, A. L.; Hanks, G. E. Prostate specific antigen nadir following external beam radiation therapy for clinically localized prostate cancer: The relationship between nadir level and disease-free survival. J. Urol. 156:450-453; 1996.
9. Partin, A. W.; Carter, H. B.; Chan, D. W.; Epstein, J. I.; Oesterling, J. E.; Rock, R. C.; Weber, J. P.; Walsh, P. C. Prostate specific antigen in the staging of localized prostate cancer: Influence of tumor differentiation, tumor volume and benign hyperplasia. J. Urol. 143:747-752; 1990.
10. Pilepich, M. V.; Caplan, R.; Byhardt, R. W.; Lawton, C. A.; Gallagher, M. J.; Mesic, J. B.; Hanks, G. E.; Coughlin, C. T.; Porter, A. Phase III trial of androgen suppression using goserelin in unfavorable prognosis carcinoma of the prostate treated with definitive radiotherapy (Report of RTOG 85-31) (Abstr.). Proceedings Annual Meeting Society Clinical Oncology. 14:1995; 631.
11. Pilepich, M. V.; Krall, J. M.; Al-Sarraff, M.; John, M. J.; Doggett, R. L.; Sause, W. T.; Lawton, C. A.; Abrams, R. A.; Rotman, M.; Rubin, P.; Shipley, W. U.; Grignon, D.; Caplan, R.; Cox, J. D. Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: A randomized comparative trial of the Radiation Therapy Oncology Group. Urology 45:616-623; 1995.
12. Pisansky, T. M.; Cha, S. S.; Earle, J. D.; Durr, E. D.; Kozelsky, T. F.; Wieand, H. S.; Oesterling, J. E. Prostate-specific antigen as a pretherapy prognostic factor in patients treated with radiation therapy for clinically localized prostate cancer. J. Clin. Oncol. 11:2158-2166; 1993.
13. Ritter, M. A.; Messing, E. M.; Shanahan, T. G.; Potts, S.; Chappell, R. J.; Kinsella, T. J. Prostate-specific antigen as a predictor of radiotherapy response and patterns of failure in localized prostate cancer. J. Clin. Oncol. 10:1208-1217; 1992.
14. Russell, K. J.; Dunatov, C.; Hafermann, M. D.; Griffeth, J. T.; Polissar, L.; Pelton, J.; Cole, S. B.; Taylor, E. W.; Wiens, L. W.; Koh, W. J.; Austin-Seymour, M. M.; Griffin, B. R.; Russell, A. H.; Laramore, G. E.; Griffin, T. W. Prostate specific antigen in the management of patients with localized adenocarcinoma of the prostate treated with primary radiation therapy. J. Urol. 146:1046-1052; 1991.
15. Sandler, H. M.; McLaughlin, P. W.; Kish, K. E.; Lichter, A. S. Results of 3D conformal radiotherapy in the treatment of 707 patients with localized prostate cancer (Abstr.). Proceedings of the 37th Annual ASTRO Meeting. 1996; 141.
16. Stamey, T. A.; Kabalin, N. J.; McNeal, J. E.; Johnstone, I. M.; Freiha, F.; Redwine, E. A.; Yang, N. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate: II. Radical prostatectomy treated patients. J. Urol. 141:1076-1083; 1989.
17. Zagars, G. Prostate-specific antigen as a prognostic factor for prostate cancer treated by external beam radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 23:47-53; 1992.
18. Zagars, G. K.; Pollack, A.; Kavadi, V. S.; von Eschenbach, A. C. Prostate-specific antigen and radiation therapy for clinically localized prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 32:293-306; 1995.
19. Zagars, G. K.; Pollack, A. P. Radiation therapy for T1 and T2 prostate cancer: Prostate-specific antigen and disease outcome. Urology 45:476-483; 1995.
20. Zagars, G. K.; von Eschenbach, A. C. Prostate-specific antigen: An important marker for prostate cancer treated by external beam radiotherapy. Cancer 72:538-548; 1993.
21. Zeitman, A. L.; Coen, J. J.; Shipley, W. U.; Willett, C. G.; Efird, J. T. Radical radiation therapy in the management of prostatic adenocarcinoma: The initial prostate specific antigen value as a predictor of treatment outcome. J. Urol. 151:640-645; 1994.